A step towards treating KRAS-mutant NSCLC

被引：8
|
作者：
Goldberg, Sarah B. [1 ,2 ]
Schlessinger, Joseph [1 ,3 ]
Boyer, Julie L. [1 ,2 ]
Herbst, Roy S. [1 ,2 ,3 ]
机构：
[1] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 01期
关键词：
CELL LUNG-CANCER; DOCETAXEL; TRIAL;
D O I：
10.1016/S1470-2045(12)70528-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：4
相关论文
共 50 条
  • [31] Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Jeanson, Arnaud
    Tomasini, Pascale
    Souquet-Bressand, Maxime
    Brandone, Nicolas
    Boucekine, Mohamed
    Grangeon, Mathieu
    Chaleat, Solene
    Khobta, Natalyia
    Milia, Julie
    Mhanna, Laurent
    Greillier, Laurent
    Biemar, Julie
    Nanni, Isabelle
    Ouafik, L'houcine
    Garcia, Stephane
    Mazieres, Julien
    Barlesi, Fabrice
    Mascaux, Celine
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1095 - 1101
  • [32] Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair
    Baglivo, Sara
    Baldelli, Elisa
    Crino, Lucio
    Ludovini, Vienna
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Hodge, Alex
    Siggillino, Annamaria
    Tofanetti, Francesca Romana
    Dong, Ting
    Pistola, Lorenza
    Bianconi, Fortunato
    Sidoni, Angelo
    Minotti, Vincenzo
    Petricoin, Emanuel
    Pierobon, Mariaelena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S360 - S361
  • [33] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    Chinese Journal of Cancer, 2016, 35 (11) : 571 - 573
  • [34] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Pang, Xiufeng
    Liu, Mingyao
    CHINESE JOURNAL OF CANCER, 2016, 35 : 92
  • [35] A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer
    Zhao, Xiao
    Wang, Xiuchao
    Fang, Lijun
    Lan, Chungen
    Zheng, Xiaowei
    Wang, Yongwei
    Zhang, Yinlong
    Han, Xuexiang
    Liu, Shaoli
    Cheng, Keman
    Zhao, Ying
    Shi, Jian
    Guo, Jiayi
    Hao, Jihui
    Ren, He
    Nie, Guangjun
    CANCER LETTERS, 2017, 402 : 61 - 70
  • [36] KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil
    De Marchi, P.
    Aguiar, P., Jr.
    Paes, R. Duarte
    Montella, T.
    Afonso, N. Gimenes
    Negreiros, I. Santos
    Vasconcelos Visani, F. L.
    Barcellos, I. Favato
    Viana Veloso, G. G.
    Reis, M. Xavier
    Mathias, C.
    Zalis, M.
    Dienstmann, R.
    Ferreira, C. Gil
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S453 - S453
  • [37] Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
    Hara, Toshifumi
    Jones, Matthew F.
    Subramanian, Murugan
    Li, Xiao Ling
    Ou, Oliver
    Zhu, Yuelin
    Yang, Yuan
    Wakefield, Lalage M.
    Hussain, S. Perwez
    Gaedcke, Jochen
    Ried, Thomas
    Luo, Ji
    Caplen, Natasha J.
    Lal, Ashish
    ONCOTARGET, 2014, 5 (17) : 7635 - 7650
  • [38] Personalizing KRAS-Mutant Allele-Specific Therapies
    Falcomata, Chiara
    Schneider, Guenter
    Saur, Dieter
    CANCER DISCOVERY, 2020, 10 (01) : 23 - 25
  • [39] DUAL CHECKPOINT ABROGATION IS SYNERGISTIC IN KRAS-MUTANT CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 903 - 903
  • [40] Accurins are endocytosed by KRAS-mutant cells via macropinocytosis
    Cullis, Jane E.
    Taylor, Laura
    Low, Susan
    Bar-Sagi, Dafna
    CANCER RESEARCH, 2016, 76
12345